Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The AHI1 divergent transcript (AHI1-DT, also known as LINC00271) is a long noncoding RNA transcribed from the genome but not translated into protein[3]. LncRNAs are typically over 200 nucleotides, often contain multiple exons, are spliced, and may have 5′ caps and 3′ poly-A tails. They can regulate gene expression through interactions with DNA, miRNA, mRNA, and proteins, exerting effects such as modifying chromatin structure, epigenetic regulation, acting as molecular sponges for miRNA, and participating in transcriptional and post-transcriptional control[1]. However, AHI1-DT itself has not been specifically characterized in terms of disease or drug interaction in the available sources, and thus cannot be considered a conventional therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 271 (AHI1 divergent transcript) (AHI1-DT).